

Tuberculosis profile: Republic of Moldova

Population 2019: 4 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	3 200 (2 800-3 700)	80 (68-92)
HIV-positive TB incidence	340 (280-410)	8.4 (6.9-10)
MDR/RR-TB incidence**	1 400 (1 100-1 600)	34 (28-40)
HIV-negative TB mortality	200 (170-230)	4.9 (4.1-5.7)
HIV-positive TB mortality	55 (38-74)	1.4 (0.95-1.8)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	33% (30-35)
Previously treated cases	60% (56-64)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	8% (6-10)

TB case notifications, 2019

Total new and relapse	2 809
- % tested with rapid diagnostics at time of diagnosis	100%
- % with known HIV status	99%
- % pulmonary	90%
- % bacteriologically confirmed ^	71%
- % children aged 0-14 years	4%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	25%
- % men	71%
Total cases notified	3 255

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	295	11%
- on antiretroviral therapy	260	88%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	96%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	44%
Laboratory-confirmed cases - MDR/RR-TB ^^	655
Patients started on treatment - MDR/RR-TB ^^	655
Laboratory-confirmed cases - XDR-TB ^^	49
Patients started on treatment - XDR-TB ^^	37
MDR/RR-TB cases tested for resistance to any fluoroquinolone	559

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	85%	2 312
Previously treated cases, excluding relapse, registered in 2018	47%	131
HIV-positive TB cases registered in 2018	69%	154
MDR/RR-TB cases started on second-line treatment in 2017	56%	962
XDR-TB cases started on second-line treatment in 2017	32%	62

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	15%
---	-----



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 89% (82-98)

TB financing

National TB budget, 2020 (US\$ millions)	13
- Funding source, domestic	77%
- Funding source, international	23%
- unfunded	0%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)